Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | J&J drops Addex's epilepsy treatment after flunking in Phase II | 7 | Pharmaceutical Technology | ||
Mo | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
Mo | Addex-Partner Janssen Pharma stellt Epilepsie-Programm nach Rückschlag ein | 7 | cash | ||
Mo | Addex's Partner J&J Innovative Medicine Discontinues ADX71149 Development In Epilepsy | 2 | RTTNews | ||
Mo | Addex Therapeutics: Addex's Partner Janssen Pharma Discontinues ADX71149 development in Epilepsy | 105 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio... ► Artikel lesen | |
19.07. | J&J ends work on Addex epilepsy drug candidate ADX71149: report | 6 | Seeking Alpha | ||
18.07. | J&J drops Addex-partnered epilepsy drug after reviewing failed phase 2 trial data | 6 | FierceBiotech | ||
15.07. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.07. | Addex Therapeutics Presents Positive Results From GABAB PAM Cough Program | 4 | RTTNews | ||
15.07. | Addex Therapeutics: Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) | 69 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a... ► Artikel lesen | |
12.07. | Addex Therapeutics: Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) | 5 | GlobeNewswire (USA) | ||
01.07. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
01.07. | Addex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General Meeting | 74 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based... ► Artikel lesen | |
06.06. | Earnings call: Addex Therapeutics reports on Q1 2024 with mixed results | 4 | Investing.com | ||
06.06. | Addex fokussiert sich nach Verlust im Q1 auf Pipeline | 332 | Moneycab | Genf - Das Biotechunternehmen Addex ist mit einem erneuten Verlust in das neue Geschäftsjahr gestartet. Ende April hatte das Unternehmen zudem einen Forschungsrückschlag einstecken müssen, der sich... ► Artikel lesen | |
06.06. | Addex Therapeutics GAAP EPS of -CHF 0.01, revenue of CHF 0.24M | 1 | Seeking Alpha | ||
06.06. | Addex Therapeutics Q1 Net Loss Widens, Income Drops | 1 | RTTNews | ||
06.06. | Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update | 76 | GlobeNewswire (Europe) | GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics... ► Artikel lesen | |
05.06. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
05.06. | Addex Therapeutics: Addex Convenes Annual General Meeting 2024 | 3 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 27,465 | -0,24 % | Bayer-Aktie an DAX-Spitze: Charttechnisch spannend | Mit einem Plus von gut drei Prozent rangiert das Papier von Bayer zu Wochenbeginn an der Spitze im DAX. Neuigkeiten von Unternehmens- oder Analystenseite, die die recht deutlichen Kursaufschläge begründen... ► Artikel lesen | |
NOVO NORDISK | 116,52 | -0,14 % | Diese Aktie schlägt Novo Nordisk um Längen | Für die Medikamente von Novo Nordisk gegen Fettleibigkeit (Adipositas) und Diabetes werden immer neue Anwendungsgebiete gefunden: Die Bestseller Ozempic und Wegovy verkaufen sich wie warme Semmeln -... ► Artikel lesen | |
GILEAD SCIENCES | 70,88 | -0,08 % | Gilead's Twice-yearly Injection Offers 100% Protection Against HIV In Women: Study | FOSTER CITY (dpa-AFX) - In a recent study conducted by Gilead Sciences, Inc. (GILD) and published in the New England Journal of Medicine, it was revealed that a biannual injection of lenacapavir... ► Artikel lesen | |
AURORA CANNABIS | 5,410 | -0,55 % | Vor den Zahlen: Bahnt sich bei Canopy Growth, Aurora Cannabis & Co. die Trendwende an? | © Foto: adobe.stock.comDie US-Wahlen werfen ihre Schatten voraus. Auch im Cannabis-Sektor verfolgt man die aktuellen Entwicklungen mit Argusaugen. Zuletzt ließ eine Meldung die Kurse von Canopy Growth... ► Artikel lesen | |
CANOPY GROWTH | 6,750 | +0,45 % | Stocks in Play: Canopy Growth Corporation | ||
TILRAY BRANDS | 1,681 | -0,53 % | Tilray Brands, Inc.: Tilray erhält erste neue Cannabis-Anbaulizenz in Deutschland nach neuen Vorschriften | Aphria RX-Anlage von Tilray in Deutschland erhält neue Cannabis-Anbaulizenz, die eine ca. 5-fache Produktionssteigerung und neue Sorten ermöglicht, um den Zugang für Patienten im ganzen Land zu verbessern
Aphria... ► Artikel lesen | |
TEVA | 15,750 | -0,32 % | Teva Pharmaceutical Industries Limited: Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease | Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment
Topline results for both UC and CD now anticipated in Q4 2024... ► Artikel lesen | |
CRONOS GROUP | 2,202 | -1,43 % | Cronos Group Inc: Cronos to hold Q2 results call Aug. 8 | ||
SYNBIOTIC | 7,620 | -2,31 % | Höhenrausch: Erlebt der "Green Rush" jetzt eine Renaissance? | ||
EYEPOINT PHARMACEUTICALS | 8,750 | +4,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
INCYTE | 63,54 | +0,54 % | Analyst Ratings For Incyte | ||
SNDL | 2,086 | +0,87 % | SNDL Inc.: SNDL Acquires Delta 9 Cannabis' Debt, Ascends to Senior Secured Creditor Status | CALGARY, AB, July 5, 2024 /PRNewswire/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or "The Company") today announced that it has completed the acquisition (the "Debt Acquisition") of the principal indebtedness... ► Artikel lesen | |
GRIFOLS | 9,216 | +0,94 % | XFRA OZTA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 13,650 | -0,73 % | Assembly Biosciences, Inc.: Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection | SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 1,276 | +0,79 % | Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 | - NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism -
- IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half... ► Artikel lesen |